Quarterly report · Q3
2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥20.5bn | 2023-01-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥6.5bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥17.4bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12.8bn | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.6bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥6.8bn | 2023-01-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.3bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.5bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥490m | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥6.4bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.3bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥768m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.2bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥433m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.2bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥554m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥389m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥400m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.8bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥790m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | −¥868m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥324m | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥126m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥48.5bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥33.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥36.5bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥21.9bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥14.1bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥26.6bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥22.0bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.3bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥24.2bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥22.9bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥18.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥12.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥4.4bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥393m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥163m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥3.7bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥4.1bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.9bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥5.0bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥646m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥299m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥46.61 | 2023-01-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥11.68 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥22.67 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.42 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥46.13 | 2023-01-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥11.33 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.11 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥22.46 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.28 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 50.0% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.8% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.8% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-09-30 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-09-30 | −¥24m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥24m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥888m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥5.9bn |
| —segment total | revenue | 2023-01-01 → 2023-09-30 | ¥20.6bn |
| —segment total | revenue external | 2023-01-01 → 2023-09-30 | ¥20.5bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥24m |
| —segment total | segment profit | 2023-01-01 → 2023-09-30 | ¥6.8bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥699m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥796m |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 682
| Item | Context | Value | Unit |
|---|---|---|---|
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03（6214）3600（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役CFO 北川 智哉 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目２番２号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03（6214）3600（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役CFO 北川 智哉 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05712 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 21600 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Filer name in english | FilingDateInstant | GNI Group Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Current period end date | FilingDateInstant | 2023-09-30 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-01-01 | |
| Comparative period end date | FilingDateInstant | 2022-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |